Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (GLYC)
NASDAQ:GLYC
GlycoMimetics (GLYC) Stock Price & Analysis
806 Followers
GLYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $3.53
Previous Close$1.8
Volume1.23M
Average Volume (3M)434.97K
Market Cap
$116.01M
Enterprise Value$75.02M
Total Cash (Recent Filing)$41.80M
Total Debt (Recent Filing)$808.40K
Price to Earnings (P/E)-3.1
Beta2.29
Next Earnings
May 02, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding64,450,385
10 Day Avg. Volume845,893
30 Day Avg. Volume434,971
Standard Deviation0.35
R-Squared0.11
Alpha-0.00711
Financial Highlights & Ratios
Price to Book (P/B)3.23
Price to Sales (P/S)11601.07
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.50K
Enterprise Value/Gross Profit7.50K
Enterprise Value/Ebitda-2.09
Forecast
1Y Price Target
$7.00Price Target Upside281.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
GlycoMimetics News
PremiumCompany Announcements
GlycoMimetics Provides Update with Investor Presentation
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive Phase 3 data readout for uproleselan in acute myeloid leukemia could lead to a New Drug Application filing, signifying progress towards market approval.
Financial StabilityThe company has a sufficient cash runway through the next year, which provides stability and time for further development.
Strategic PartnershipsNew research collaborations could enhance the development of GMI-1687 for Sickle Cell Disease, expanding the company's therapeutic portfolio.
Bears Say
Clinical Trial ProgressOngoing Phase 3 trial encountered a delay in hitting the primary endpoint of overall survival as patients are living longer than expected.
Financial PerformanceGlycomimetics reported a significant net loss for the fourth quarter.
Upcoming Data ReleaseThe topline data for a Phase 3 study in refractory/relapsed acute myeloid leukemia may be viewed as a binary event, introducing a level of risk.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GLYC FAQ
What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $1.11 and its highest was $3.53 in the past 12 months.
What is GlycoMimetics’s market cap?
Currently, no data Available
When is GlycoMimetics’s upcoming earnings report date?
GlycoMimetics’s upcoming earnings report date is May 02, 2024 which is in 8 days.
How were GlycoMimetics’s earnings last quarter?
GlycoMimetics released its earnings results on Mar 27, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.152 by $0.012.
Is GlycoMimetics overvalued?
According to Wall Street analysts GlycoMimetics’s price is currently Undervalued.
Does GlycoMimetics pay dividends?
GlycoMimetics does not currently pay dividends.
What is GlycoMimetics’s EPS estimate?
GlycoMimetics’s EPS estimate is -$0.15.
How many shares outstanding does GlycoMimetics have?
GlycoMimetics has 64,450,386 shares outstanding.
What happened to GlycoMimetics’s price movement after its last earnings report?
GlycoMimetics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.152. Following the earnings report the stock price went up 11.579%.
Which hedge fund is a major shareholder of GlycoMimetics?
Currently, no hedge funds are holding shares in GLYC
---
GlycoMimetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (281.47% Upside)
$7.00 (281.47% Upside)
Blogger Sentiment
Bullish
GLYC Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 13.6%
Last 30 Days ▲ 13.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.00%
12-Months-Change
Fundamentals
Return on Equity
-90.72%
Trailing 12-Months
Asset Growth
-12.53%
Trailing 12-Months
Company Description
GlycoMimetics
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
---
GLYC Earnings Call
Q4 2024
0:00 / 0:00
---
GLYC Stock 12 Months Forecast
Average Price Target
$7.00
▲(281.47% Upside)
Technical Analysis
Best Analysts Covering GLYC
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+15.26%
reiterated a buy rating 29 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +15.26% per trade.
---